The Cigna Group
—- Market cap
- $74.23B
- Debt
- —
- Cash
- −$7.68B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: CI stock price vs TFX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TFX's multiple
Needs TFX P/E.
Implied fair value · at CI's multiple
Needs Annual EPS is negative.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 68% equity / 32% debt · EV / Revenue 3.94x · EV proxy / EBITDA proxy 26.53x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
TELEFLEX INCORPORATED · implied price per share
Bear
-$24.97
Base
-$21.78
Bull
-$16.12
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
CI vs UNH
CVS HEALTH Corp
CI vs CVS
HUMANA INC
CI vs HUM
CENTENE CORP
CI vs CNC
WEST PHARMACEUTICAL SERVICES INC
CI vs WST
BAXTER INTERNATIONAL INC
CI vs BAX
ABBOTT LABORATORIES
CI vs ABT
BOSTON SCIENTIFIC CORP
CI vs BSX
Medtronic plc
CI vs MDT
STRYKER CORP
CI vs SYK
DENTSPLY SIRONA Inc.
CI vs XRAY
RESMED INC
CI vs RMD
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CI can sustain positive mid-to-high single digit profitability and growth while TFX remains loss-making, then favor CI because the valuation comparison shows CI trading at a far lower P/S multiple despite materially stronger earnings, growth, and ROIC.
The valuation gap is extraordinarily wide: CI trades at 0.3x P/S versus TFX at 3.0x P/S, and the provided implied price for CI is $3,128.82 versus a current price of $290.49. CI is also within its historical band, which suggests the market is not pricing in a major dislocation in CI itself, while TFX-based framework implies a very large re-rating differential.
Supporting Metrics